PMID- 37975201
OWN - NLM
STAT- MEDLINE
DCOM- 20240104
LR  - 20240321
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 103
IP  - 1
DP  - 2024 Jan
TI  - Outcomes of non-flow-limiting spiral dissection after drug-coated balloon 
      angioplasty for de novo femoropopliteal lesions.
PG  - 97-105
LID - 10.1002/ccd.30911 [doi]
AB  - BACKGROUND: Whether drug-coated balloon (DCB) angioplasty would be effective in 
      spiral dissection (SD) lesions with no flow impairment has been thoroughly 
      investigated. AIMS: The present study sought to assess the clinical outcomes of 
      non-flow-limiting SD after DCB angioplasty for de novo femoropopliteal lesions in 
      patients with symptomatic lower extremity artery disease. METHOD: This 
      single-center retrospective study enrolled 497 patients with non-flow-limiting SD 
      (n = 92) or non-SD (n = 405) without bailout stenting. The primary endpoint was 
      1-year primary patency, with the secondary endpoints including freedom from 
      target lesion revascularization (TLR), major adverse limb event (MALE), all-cause 
      death, and 30-day restenosis. RESULTS: The 1-year primary patency and freedom 
      from TLR were significantly lower in the SD group than in the non-SD group (69.8% 
      vs. 83.3%, p = 0.004; 78.7% vs. 93.0%, p = 0.007, respectively). The SD group had 
      a higher incidence of MALE and 30-day restenosis than the non-SD group (24.6% vs. 
      11.9%, p = 0.001; 4.3% vs. 0.5%, p = 0.002, respectively). All-cause death was 
      comparable. One-year restenosis after SD was associated with chronic 
      limb-threatening ischemia (CLTI) (hazard ratio, 3.36 [95% confidence interval, 
      1.21-9.36]; p = 0.020), TASC Ⅱ D (hazard ratio, 3.97 [95% confidence interval, 
      1.02-15.52]; p = 0.047), and residual stenosis >/=50% (hazard ratio, 4.92 [95% 
      confidence interval, 1.01-23.94]; p = 0.048). The incidence of restenosis after 
      SD increased with the number of these risk factors. CONCLUSIONS: Despite normal 
      antegrade flow, the 1-year primary patency rate after DCB angioplasty for de novo 
      femoropopliteal lesions was significantly lower in lesions with SD than those 
      without SD. CLTI, TASC II D, and residual stenosis >/=50% were risk factors 
      associated with 1-year restenosis after DCB angioplasty for non-flow-limiting SD 
      lesions.
CI  - (c) 2023 The Authors. Catheterization and Cardiovascular Interventions published by 
      Wiley Periodicals LLC.
FAU - Haraguchi, Takuya
AU  - Haraguchi T
AUID- ORCID: 0000-0002-2116-2178
AD  - Department of Cardiology, Asia Medical Group, Sapporo Heart Center, Sapporo 
      Cardio Vascular Clinic, Sapporo, Japan.
FAU - Kuramitsu, Shoichi
AU  - Kuramitsu S
AD  - Department of Cardiology, Asia Medical Group, Sapporo Heart Center, Sapporo 
      Cardio Vascular Clinic, Sapporo, Japan.
FAU - Tsujimoto, Masanaga
AU  - Tsujimoto M
AD  - Department of Cardiology, Asia Medical Group, Sapporo Heart Center, Sapporo 
      Cardio Vascular Clinic, Sapporo, Japan.
FAU - Kashima, Yoshifumi
AU  - Kashima Y
AUID- ORCID: 0000-0002-9715-0472
AD  - Department of Cardiology, Asia Medical Group, Sapporo Heart Center, Sapporo 
      Cardio Vascular Clinic, Sapporo, Japan.
FAU - Sato, Katsuhiko
AU  - Sato K
AD  - Department of Cardiology, Asia Medical Group, Sapporo Heart Center, Sapporo 
      Cardio Vascular Clinic, Sapporo, Japan.
FAU - Fujita, Tsutomu
AU  - Fujita T
AD  - Department of Cardiology, Asia Medical Group, Sapporo Heart Center, Sapporo 
      Cardio Vascular Clinic, Sapporo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231117
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Coated Materials, Biocompatible)
SB  - IM
MH  - Humans
MH  - Femoral Artery/diagnostic imaging
MH  - Popliteal Artery/diagnostic imaging
MH  - Constriction, Pathologic
MH  - Retrospective Studies
MH  - *Peripheral Arterial Disease/diagnostic imaging/therapy
MH  - Treatment Outcome
MH  - *Angioplasty, Balloon/adverse effects
MH  - Coated Materials, Biocompatible
MH  - Vascular Patency
OTO - NOTNLM
OT  - drug-coated balloon
OT  - endovascular treatment
OT  - femoropopliteal lesions
OT  - lower extremity artery disease
OT  - spiral dissection
EDAT- 2023/11/17 15:24
MHDA- 2024/01/04 11:44
CRDT- 2023/11/17 04:33
PHST- 2023/10/17 00:00 [revised]
PHST- 2023/07/05 00:00 [received]
PHST- 2023/11/05 00:00 [accepted]
PHST- 2024/01/04 11:44 [medline]
PHST- 2023/11/17 15:24 [pubmed]
PHST- 2023/11/17 04:33 [entrez]
AID - 10.1002/ccd.30911 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2024 Jan;103(1):97-105. doi: 10.1002/ccd.30911. Epub 
      2023 Nov 17.